Burning Rock Biotech Limited (BNR)
| Market Cap | 128.67M +26.1% |
| Revenue (ttm) | 73.70M -6.7% |
| Net Income | -10.01M |
| EPS | -0.95 |
| Shares Out | 10.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,560 |
| Open | 11.70 |
| Previous Close | 11.62 |
| Day's Range | 11.21 - 12.31 |
| 52-Week Range | 6.79 - 41.72 |
| Beta | 1.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 10, 2026 |
About BNR
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cance... [Read more]
Financial Performance
In 2025, Burning Rock Biotech's revenue was 539.57 million, an increase of 4.60% compared to the previous year's 515.82 million. Losses were -55.35 million, -84.03% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Burning Rock Reports Second Quarter 2026 Financial Results
GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NG...
Burning Rock Biotech Earnings release: Q2 2026
Burning Rock Biotech released its Q2 2026 earnings on September 10, 2026, summarizing the period's financial results.
Burning Rock Biotech Slides: Q2 2026
Burning Rock Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 10, 2026.
Burning Rock Biotech CEO Yusheng Han purchases 73,141 ADSs for $618,217
Burning Rock Biotech (BNR) announced that its founder, chairman of the board of directors and chief executive officer, Yusheng Han, has purchased 73,141 of the company’s ADSs for $618,217.72 from…
Burning Rock Announces Founder's Purchase of Its ADSs
GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NG...
Burning Rock Reports First Quarter 2026 Financial Results
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS...
Burning Rock Biotech Earnings release: Q1 2026
Burning Rock Biotech released its Q1 2026 earnings on June 9, 2026, summarizing the period's financial results.
Burning Rock Biotech Slides: Q1 2026
Burning Rock Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 9, 2026.
Burning Rock Publishes 2025 Annual Report on Form 20-F
GUANGZHOU, China, April 28, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing tec...
Burning Rock Biotech founder and CEO purchases company ADSs
Burning Rock Biotech’s (BNR) founder, chairman of the board and CEO, Yusheng Han, has purchased 31,487 of the company’s ADSs for $546,603.90 from the open market, in compliance with the…
Burning Rock Biotech reports Q4 EPS (RMB0.16) vs. (RMB0.79) last year
Reports Q4 revenue RMB126.3M vs. RMB126M last year.
Burning Rock Biotech Annual report: Q4 2025
Burning Rock Biotech has published its Q4 2025 annual report on March 12, 2026.
Burning Rock Biotech Earnings release: Q4 2025
Burning Rock Biotech released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Burning Rock Biotech Slides: Q4 2025
Burning Rock Biotech has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
Burning Rock Biotech CEO Yusheng Han purchases $811,721 of ADSs
Burning Rock Biotech (BNR) announced that as of the date of this press release, its founder, chairman of the board of directors and chief executive officer, Yusheng Han, has purchased…
Burning Rock Announces Results of 2025 Annual General Meeting
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NG...
Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NG...
Burning Rock Biotech Earnings release: Q3 2025
Burning Rock Biotech released its Q3 2025 earnings on November 20, 2025, summarizing the period's financial results.
Burning Rock Biotech Slides: Q3 2025
Burning Rock Biotech has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 20, 2025.
Burning Rock Reports Third Quarter 2025 Financial Results
GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS...
Burning Rock announces OncoGuide OncoScreen Plus CDx System approval in Japan
Riken Genesis and Burning Rock Biotech (BNR) announced that the OncoGuide OncoScreen Plus CDx System based on OncoScreen Plus to be used as a companion diagnostic for AstraZeneca’s (AZN) capivasertib…
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd.
Burning Rock Biotech Earnings release: Q2 2025
Burning Rock Biotech released its Q2 2025 earnings on September 8, 2025, summarizing the period's financial results.
Burning Rock Biotech Slides: Q2 2025
Burning Rock Biotech has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on September 8, 2025.
Burning Rock Reports Second Quarter 2025 Financial Results
GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NG...